Key Takeaways
- • Abivax (NASDAQ: ABVX) shares surged over 580% in a single trading session in July 2025, delivering outsized gains to healthcare-focused hedge funds positioned in the biotech stock.
- • ADAR1 Capital Management and Deep Track Capital each captured significant returns from the Abivax spike, posting July gains of 18% and 8% respectively, driven substantially by exposure to the drugmaker's explosive price move.
- • The surge in an obscure drugmaker's equity represents a rare concentrated win for biotech-focused hedge funds during 2025, offsetting broader sector volatility and regulatory headwinds that have pressured many biotech positions throughout the year.
- • Hedge funds betting on pharmaceutical and biotech equities have navigated a challenging 2025 environment marked by regulatory concerns and sector-wide selloffs, making concentrated wins like Abivax increasingly valuable for fund performance.
Summary
An obscure biopharmaceutical company's stock delivered a blockbuster one-day rally on July 2025, generating substantial returns for healthcare-specialized hedge funds. Abivax (NASDAQ: ABVX) shares spiked more than 580% in a single trading session, a rare magnitude of gain that lifted the performance of multiple dedicated biotech hedge funds during a year characterized by significant sector volatility and regulatory pressures.
ADAR1 Capital Management and Deep Track Capital were among the primary beneficiaries of the Abivax surge. ADAR1 posted an 18% gain in July driven substantially by the position, while Deep Track Capital captured an 8% monthly return boosted by exposure to the drugmaker. The magnitude of the single-day move—more than sixfold appreciation—demonstrates the outsized impact concentrated positions in lower-capitalization biotech equities can deliver to specialized hedge funds focused on pharmaceutical innovation.
The Abivax rally provided a significant bright spot for biotech-focused hedge funds navigating a challenging investment landscape. Throughout 2025, hedge funds holding biotech and pharmaceutical equities have contended with regulatory concerns, clinical trial setbacks, and broader sector headwinds that have resulted in double-digit percentage losses for some managers. The wave of merger-and-acquisition activity by major pharmaceutical companies has created pockets of opportunity, but concentrated bets on smaller-cap drugmakers remain inherently volatile.
The extreme 580% single-session move underscores the risk-reward dynamics of small-cap biotech investing. While such gains can meaningfully enhance annual fund performance, positions in obscure drugmakers carry elevated execution risk tied to clinical trial outcomes, regulatory approvals, and company-specific catalysts. For ADAR1 and Deep Track Capital, the Abivax position materialized into a material performance contribution during a year when biotech sector returns have been inconsistent and often negative for many institutional investors.
ADAR1 Capital Management and Deep Track Capital were among the primary beneficiaries of the Abivax surge. ADAR1 posted an 18% gain in July driven substantially by the position, while Deep Track Capital captured an 8% monthly return boosted by exposure to the drugmaker. The magnitude of the single-day move—more than sixfold appreciation—demonstrates the outsized impact concentrated positions in lower-capitalization biotech equities can deliver to specialized hedge funds focused on pharmaceutical innovation.
The Abivax rally provided a significant bright spot for biotech-focused hedge funds navigating a challenging investment landscape. Throughout 2025, hedge funds holding biotech and pharmaceutical equities have contended with regulatory concerns, clinical trial setbacks, and broader sector headwinds that have resulted in double-digit percentage losses for some managers. The wave of merger-and-acquisition activity by major pharmaceutical companies has created pockets of opportunity, but concentrated bets on smaller-cap drugmakers remain inherently volatile.
The extreme 580% single-session move underscores the risk-reward dynamics of small-cap biotech investing. While such gains can meaningfully enhance annual fund performance, positions in obscure drugmakers carry elevated execution risk tied to clinical trial outcomes, regulatory approvals, and company-specific catalysts. For ADAR1 and Deep Track Capital, the Abivax position materialized into a material performance contribution during a year when biotech sector returns have been inconsistent and often negative for many institutional investors.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.